1 published article · Updated continuously
19 trials tracked for Male hypogonadism: 14 in phase 3 or 4 and 8 with published results. The most-cited published study has 81 citations.
Showing the 19 most-cited and recently-updated of 19 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Treatment with various testosterone formulations has demonstrated efficacy in improving hormonal profiles and clinical markers. Natesto was associated with a change of 652 in testosterone levels, 21.6 in estradiol levels, and 3.0 to 2.6 in gonadotropin levels over 27 weeks 3. Oral testosterone undecanoate showed high success rates in achieving average serum testosterone concentrations between 300 and 1000 ng/dL (83.6% and 79.2%) 9.
Specific testosterone interventions demonstrated significant reach in clinical targets. LPCN 1021 treatment resulted in 80% of subjects achieving average total testosterone concentrations in the normal range 7 and 69% of subjects reaching the same target in another study 12. Additionally, oral SOV2012-F1 was shown to maintain average plasma total testosterone within the normal range in 166% of male hypogonadal subjects 11.
Clinical outcomes for specific formulations include a change of 4.8 in IIEF-6 scores with Testosterone Cypionate 1. Regarding metabolic and physical markers, LPCN 1021 showed significant reductions in MRI-PDFF (ranging from -13.5% to -38.5% depending on baseline levels) 6.
Safety and secondary outcomes for specific treatments include the observation that 1.4%, 1.5%, and 2.2% of patients taking Aveed required new antihypertensive medications, while 0% required dose increases 2. SOV2012-F1 was associated with consistent changes in ambulatory systolic blood pressure (approximately 128.9 to 130.7) and diastolic blood pressure (approximately 76.2 to 76.9) over 120 to 180 days 10.
AI synthesis of 11 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
